Upstream Bio, Inc. (UPB) Stock Price & Analysis
Upstream Bio, Inc. (UPB) rose 0.16% to USD 6.41 as of July 25, 2026 at 04:33 UTC, according to Nexqual real-time market data.
UPB last closed at USD 6.4; the session ranged USD 6.16–6.61 on volume of 597,337 shares. Market capitalization is $348.83M, with a 52-week range of USD 5.85–33.68 (NMS). Source: Nexqual, July 25, 2026 at 04:33 UTC.
Key Statistics (as of July 25, 2026 at 04:33 UTC)
| Price | USD 6.41 |
|---|---|
| Change | ▲ 0.16% (up) |
| Previous Close | USD 6.4 |
| Open | USD 6.4 |
| Day Range | USD 6.16 – 6.61 |
| 52-Week Range | USD 5.85 – 33.68 |
| Volume | 597,337 shares |
| Market Cap | $348.83M |
| Exchange | NMS |
Technical Analysis (UPB)
Nexqual's technical model rates UPB "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:33 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.24 (neutral) |
| vs SMA50 | Below (USD 7.29) |
| MACD | -0.17 (negative) |
Analyst Ratings (UPB)
Wall Street analysts rate UPB "None" based on 8 analysts, with a mean price target of USD 38.25 (range USD 8–75), per Nexqual as of July 25, 2026 at 04:33 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 38.25 |
| High Target | USD 75 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (UPB)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.76 |
| Revenue Estimate | $377,250 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.75 vs est -0.75 ▲ beat |
| 2025-12-31 | USD -0.78 vs est -0.7 ▼ miss |
| 2025-09-30 | USD -0.63 vs est -0.78 ▲ beat |
| 2025-06-30 | USD -0.74 vs est -0.61 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:33 UTC.
Financials & Fundamentals (UPB)
| Total Revenue | $3.32M |
|---|---|
| Revenue Growth (YoY) | +82.70% |
| Gross Margin | +100.00% |
| Operating Margin | -4218.09% |
| Profit Margin | +0.00% |
| ROE | -41.83% |
| Debt / Equity | 0.37 |
| Current Ratio | 23.14 |
| Total Cash | $294.58M |
| Total Debt | $1.11M |
| Free Cash Flow | $-90.31M |
Source: Nexqual, July 25, 2026 at 04:33 UTC.
Financial Health Score (UPB)
Nexqual rates Upstream Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:33 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $295M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$90M, burning cash |
| Efficiency | Critical — ROE -42%, ROA -27.8% |
Ownership (UPB)
| Insider Ownership | +14.88% |
|---|---|
| Institutional Ownership | +88.47% |
| Shares Outstanding | 54.42M |
| Float | 40.62M |
| Short % of Float | +11.63% |
Source: Nexqual, July 25, 2026 at 04:33 UTC.
Leadership (UPB)
Upstream Bio, Inc. is led by E. Rand Sutherland M.D., M.P.H. (age 55), CEO & Director, per Nexqual as of July 25, 2026 at 04:33 UTC.
| CEO & Director | E. Rand Sutherland M.D., M.P.H. (age 55) |
|---|---|
| CFO & COO | Michael Paul Gray (age 54) |
| Chief Technology Officer | Stacy Price M.S., P.M.P. (age 56) |
| Director of Corporate Communications & Investor Relations | Meggan Buckwell |
| Senior Vice President of People & Culture | Lisa Fiering |
Major Backers & Investors (UPB)
Notable institutional backers of Upstream Bio, Inc. include FMR, LLC, Fidelity, Orbimed Advisors LLC., according to Nexqual as of July 25, 2026 at 04:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.89% |
| Fidelity | 11.47% |
| Orbimed Advisors LLC. | 10.46% |
| Decheng Capital LLC | 5.01% |
| Enavate Sciences Gp, LLC | 4.52% |
| Federated Hermes, Inc. | 2.59% |
| Millennium Management | 1.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.63% |
| Vanguard Group | 6.09% |
| Geode Capital | 1.75% |
Source: Nexqual, July 25, 2026 at 04:33 UTC.
From Upstream Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Approximately 350 million people live with asthma around the world, including more than 25 million Americans.
- The major asthma markets, including the United States, France, Spain, Germany, Italy, the United Kingdom ("UK") and Japan, have estimated annual sales of approximately $7.5 billion for 2023 with a compound annual growth rate ("CAGR") of approximately 5.9% through 2032.
- Tezepelumab is projected to reach peak global annual sales of over $3.0 billion for severe asthma alone in 2032, and had achieved more than 20% of new to brand share of prescriptions in the United States in its first commercial year.   12   Taken together, we believe the strength of the biologic market has demonstrated there is room for multiple entrants into the market and the opportunity for rapid acceleration for market share.
- Our team     6   We have built a team with deep experience and a strong track record of execution.
Partnerships
- Dupilumab alone has an annual global sales estimate for the treatment of CRSwNP of up to $1.5 billion by 2030 according to third-party research analyst reports.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | USD 27.02 | ▼ 3.36% |
| MBX | MBX Biosciences, Inc. | USD 62 | ▲ 6.35% |
| ZBIO | Zenas BioPharma, Inc. | USD 30.39 | ▼ 3.49% |
| RAPP | Rapport Therapeutics, Inc. | USD 40.68 | ▼ 1.57% |
| SEPN | Septerna, Inc. | USD 33.1 | ▼ 3.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:33 UTC. This page is informational and not investment advice.